[144] Royalty Pharma plc SEC Filing
Royalty Pharma plc submitted a Form 144 proposing the sale of 33,500 Class A ordinary shares through Merrill Lynch on NASDAQ, with an approximate sale date of 08/11/2025. The filing lists an aggregate market value of $1,213,747.00 and 432,293,050 shares outstanding, so the proposed block represents a very small fraction of the company.
The shares were acquired on 04/13/2015 in an exchange of limited partnership interests from Royalty Pharma plc, with cash payment recorded. The filer reports no securities sold in the past three months and includes the standard representation that no material nonpublic information is known.
Royalty Pharma plc ha presentato un Form 144 proponendo la vendita di 33,500 azioni ordinarie di classe A tramite Merrill Lynch su NASDAQ, con data di vendita approssimativa 08/11/2025. La comunicazione dichiara un valore di mercato aggregato di $1,213,747.00 e 432,293,050 azioni in circolazione, quindi il blocco proposto rappresenta una frazione molto piccola della societ脿.
Le azioni sono state acquisite il 04/13/2015 in uno scambio di partecipazioni in una societ脿 in accomandita da Royalty Pharma plc, con pagamento in contanti registrato. Il dichiarante segnala nessuna vendita di titoli negli ultimi tre mesi e include la rappresentazione standard che non 猫 a conoscenza di informazioni materiali non pubbliche.
Royalty Pharma plc present贸 un Form 144 proponiendo la venta de 33,500 acciones ordinarias Clase A a trav茅s de Merrill Lynch en NASDAQ, con fecha aproximada de venta 08/11/2025. La presentaci贸n indica un valor de mercado agregado de $1,213,747.00 y 432,293,050 acciones en circulaci贸n, por lo que el bloque propuesto representa una fracci贸n muy peque帽a de la compa帽铆a.
Las acciones fueron adquiridas el 04/13/2015 en un intercambio de participaciones en una sociedad comanditaria de Royalty Pharma plc, con pago en efectivo registrado. El declarante informa no haber vendido valores en los 煤ltimos tres meses e incluye la declaraci贸n est谩ndar de que no conoce informaci贸n material no p煤blica.
Royalty Pharma plc電� 33,500 Class A 氤错喌欤�鞚� 毵り皝鞚� Merrill Lynch毳� 韱淀暣 NASDAQ鞐愳劀 鞝滌晥頃橂姅 Form 144毳� 鞝滌稖頄堨溂氅�, 雽�霝奠爜鞚� 毵り皝 鞓堨爼鞚检潃 08/11/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 齑濎嫓鞛リ皜旃� $1,213,747.00鞕� 鞙犿喌欤检嫕靾� 432,293,050臧� 旮办灛霅橃柎 鞛堨柎 鞝滌晥霅� 敫旊鞚� 須岇偓 鞝勳泊鞐愳劀 毵れ毎 鞛戩潃 牍勳鞚� 彀頃╇媹雼�.
頃措嫻 欤检嫕鞚� 04/13/2015鞐� 鞙犿暅毂呾瀯臁绊暕 歆�攵勳潣 甑愴櫂鞙茧 Royalty Pharma plc搿滊秬韯� 旆摑霅橃棃鞙茧┌, 顺勱笀歆�旮夓澊 旮半霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 斓滉芳 3臧滌洈臧� 歃濌秾鞚� 毵る弰頃橃 鞎婌晿鞚�鞚� 氤搓碃頃橁碃 鞛堨溂氅�, 欷戩殧頃� 牍勱车臧� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Royalty Pharma plc a d茅pos茅 un Form 144 proposant la vente de 33,500 actions ordinaires de cat茅gorie A par l'interm茅diaire de Merrill Lynch sur le NASDAQ, avec une date de vente approximative indiqu茅e au 08/11/2025. Le dossier indique une valeur de march茅 agr茅g茅e de $1,213,747.00 et 432,293,050 actions en circulation, de sorte que le lot propos茅 repr茅sente une tr猫s petite fraction de la soci茅t茅.
Les actions ont 茅t茅 acquises le 04/13/2015 dans le cadre d'un 茅change de parts dans une soci茅t茅 en commandite aupr猫s de Royalty Pharma plc, avec un paiement en 别蝉辫猫肠别蝉 enregistr茅. Le d茅clarant signale ne pas avoir vendu de titres au cours des trois derniers mois et inclut la d茅claration standard selon laquelle il n'a connaissance d'aucune information importante non publique.
Royalty Pharma plc hat ein Form 144 eingereicht, in dem der Verkauf von 33,500 Class A-Stammaktien 眉产别谤 Merrill Lynch an der NASDAQ vorgeschlagen wird, mit einem ungef盲hren Verkaufstermin 08/11/2025. Die Einreichung nennt einen aggregierten Marktwert von $1,213,747.00 und 432,293,050 ausstehende Aktien, sodass das vorgeschlagene Paket einen sehr kleinen Anteil des Unternehmens darstellt.
Die Aktien wurden am 04/13/2015 im Rahmen eines Tauschs von Kommanditanteilen von Royalty Pharma plc erworben, wobei eine Barzahlung verbucht wurde. Der Melder gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben, und f眉gt die 眉bliche Erkl盲rung bei, dass ihm keine wesentlichen nicht-枚ffentlichen Informationen bekannt sind.
- Proposed sale size is small: 33,500 shares representing approximately 0.0078% of 432,293,050 shares outstanding
- No sales in past three months: the form reports "Nothing to Report" for securities sold during the prior 3 months
- Clear acquisition history provided: shares were acquired on 04/13/2015 in an exchange of limited partnership interests with payment in cash
- None.
Insights
TL;DR: Small Rule 144 proposed sale; unlikely to move market given size relative to outstanding shares.
The filing shows a proposed sale of 33,500 shares valued at $1,213,747 versus 432,293,050 shares outstanding, representing roughly 0.0078% of the share base. Because the block is immaterial to total capitalization, market impact should be limited. The details provided (broker, exchange, acquisition date and nature) are standard for a Form 144 and allow market participants to time and route orders appropriately.
TL;DR: Form 144 contains required disclosures and a representation about material nonpublic information; no recent sales reported.
The filer discloses acquisition on 04/13/2015 via an exchange of limited partnership interests and payment in cash, and notes "Nothing to Report" for sales in the prior three months. The submission identifies the executing broker and exchange, and includes the standard signer representation required under Rule 144, fulfilling routine compliance expectations for an intended sale under the rule.
Royalty Pharma plc ha presentato un Form 144 proponendo la vendita di 33,500 azioni ordinarie di classe A tramite Merrill Lynch su NASDAQ, con data di vendita approssimativa 08/11/2025. La comunicazione dichiara un valore di mercato aggregato di $1,213,747.00 e 432,293,050 azioni in circolazione, quindi il blocco proposto rappresenta una frazione molto piccola della societ脿.
Le azioni sono state acquisite il 04/13/2015 in uno scambio di partecipazioni in una societ脿 in accomandita da Royalty Pharma plc, con pagamento in contanti registrato. Il dichiarante segnala nessuna vendita di titoli negli ultimi tre mesi e include la rappresentazione standard che non 猫 a conoscenza di informazioni materiali non pubbliche.
Royalty Pharma plc present贸 un Form 144 proponiendo la venta de 33,500 acciones ordinarias Clase A a trav茅s de Merrill Lynch en NASDAQ, con fecha aproximada de venta 08/11/2025. La presentaci贸n indica un valor de mercado agregado de $1,213,747.00 y 432,293,050 acciones en circulaci贸n, por lo que el bloque propuesto representa una fracci贸n muy peque帽a de la compa帽铆a.
Las acciones fueron adquiridas el 04/13/2015 en un intercambio de participaciones en una sociedad comanditaria de Royalty Pharma plc, con pago en efectivo registrado. El declarante informa no haber vendido valores en los 煤ltimos tres meses e incluye la declaraci贸n est谩ndar de que no conoce informaci贸n material no p煤blica.
Royalty Pharma plc電� 33,500 Class A 氤错喌欤�鞚� 毵り皝鞚� Merrill Lynch毳� 韱淀暣 NASDAQ鞐愳劀 鞝滌晥頃橂姅 Form 144毳� 鞝滌稖頄堨溂氅�, 雽�霝奠爜鞚� 毵り皝 鞓堨爼鞚检潃 08/11/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 齑濎嫓鞛リ皜旃� $1,213,747.00鞕� 鞙犿喌欤检嫕靾� 432,293,050臧� 旮办灛霅橃柎 鞛堨柎 鞝滌晥霅� 敫旊鞚� 須岇偓 鞝勳泊鞐愳劀 毵れ毎 鞛戩潃 牍勳鞚� 彀頃╇媹雼�.
頃措嫻 欤检嫕鞚� 04/13/2015鞐� 鞙犿暅毂呾瀯臁绊暕 歆�攵勳潣 甑愴櫂鞙茧 Royalty Pharma plc搿滊秬韯� 旆摑霅橃棃鞙茧┌, 顺勱笀歆�旮夓澊 旮半霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 斓滉芳 3臧滌洈臧� 歃濌秾鞚� 毵る弰頃橃 鞎婌晿鞚�鞚� 氤搓碃頃橁碃 鞛堨溂氅�, 欷戩殧頃� 牍勱车臧� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Royalty Pharma plc a d茅pos茅 un Form 144 proposant la vente de 33,500 actions ordinaires de cat茅gorie A par l'interm茅diaire de Merrill Lynch sur le NASDAQ, avec une date de vente approximative indiqu茅e au 08/11/2025. Le dossier indique une valeur de march茅 agr茅g茅e de $1,213,747.00 et 432,293,050 actions en circulation, de sorte que le lot propos茅 repr茅sente une tr猫s petite fraction de la soci茅t茅.
Les actions ont 茅t茅 acquises le 04/13/2015 dans le cadre d'un 茅change de parts dans une soci茅t茅 en commandite aupr猫s de Royalty Pharma plc, avec un paiement en 别蝉辫猫肠别蝉 enregistr茅. Le d茅clarant signale ne pas avoir vendu de titres au cours des trois derniers mois et inclut la d茅claration standard selon laquelle il n'a connaissance d'aucune information importante non publique.
Royalty Pharma plc hat ein Form 144 eingereicht, in dem der Verkauf von 33,500 Class A-Stammaktien 眉产别谤 Merrill Lynch an der NASDAQ vorgeschlagen wird, mit einem ungef盲hren Verkaufstermin 08/11/2025. Die Einreichung nennt einen aggregierten Marktwert von $1,213,747.00 und 432,293,050 ausstehende Aktien, sodass das vorgeschlagene Paket einen sehr kleinen Anteil des Unternehmens darstellt.
Die Aktien wurden am 04/13/2015 im Rahmen eines Tauschs von Kommanditanteilen von Royalty Pharma plc erworben, wobei eine Barzahlung verbucht wurde. Der Melder gibt an, in den letzten drei Monaten keine Wertpapiere verkauft zu haben, und f眉gt die 眉bliche Erkl盲rung bei, dass ihm keine wesentlichen nicht-枚ffentlichen Informationen bekannt sind.
FAQ
What does Royalty Pharma's (RPRX) Form 144 report?
How large is the proposed sale relative to outstanding shares for RPRX?
When and how were the shares being sold acquired?
Has the filer sold any Royalty Pharma securities in the prior three months?
Which broker and market are named for the proposed sale?
